Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection
- 13 February 2021
- journal article
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 65 (11-12), 16-21
- https://doi.org/10.37489/0235-2990-2020-65-11-12-16-21
Abstract
Aim. The study evaluates clinical effectiveness and safety of etiotropic antiviral medications with a direct mechanism of action (Riamilovir, Ribavirin, Umifenovir) for the treatment of moderate SARS-CoV-2 infection in adults. Materials and methods. The study used the data from 59 health records of patients with moderate PCR-confirmed SARS-CoV-2 infection. Control group included 29 patients treated with 1250 mg Riamilovir off-label per day for 5 days (250 mg 5 times a day), comparison group consisted of 30 patients, who received 800 mg Ribavirin and Umifenovir per day for 5 days. The effectiveness of the medications was assessed by the duration and severity of general infectious and respiratory syndromes, anosmia and ageusia, as well as the oxygen content in the blood, the timing of SARS-COV-2 virus elimination from the body according to the results of control studies of nasopharyngeal swabs using the PCR method and dynamics of blood tests results. Results. A statistically significant decrease in the duration of fever, cough, and anosmia and a more rapid elimination of the virus from the body were noted in the group of patients receiving Riamilovir. Decreased levels of non-specific inflammatory markers in blood serum, as well as normal values of liver enzymes were observed in control group during therapy, as opposed to the comparison group. No serious adverse events were noted when using the medication. Conclusion. Nucleoside analogue medication Riamilovir showed good effectiveness and safety profile in adult patients with moderate SARS-CoV-2 infection.Keywords
This publication has 11 references indexed in Scilit:
- Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled TrialEngineering, 2020
- Clinical efficacy and safety of nebulized prostacyclin in patients with sARs-CoV-2 (prospective comparative study)Journal Infectology, 2020
- Cytokine Storm in COVID-19: The Current Evidence and Treatment StrategiesFrontiers in Immunology, 2020
- An Update on Current Therapeutic Drugs Treating COVID-19Current Pharmacology Reports, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- Candidate drugs against SARS-CoV-2 and COVID-19Pharmacological Research, 2020
- Favipiravir versus Arbidol for COVID-19: A Randomized Clinical TrialPublished by Cold Spring Harbor Laboratory ,2020
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering, 2020
- Medical Management of COVID-19: Evidence and ExperienceJournal of Clinical Medicine Research, 2020
- Nucleoside analogues for the treatment of coronavirus infectionsCurrent Opinion in Virology, 2019